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Abstract 
The aim was to enhance the dissolution of lornoxicam and to produce mini-tablets with an 
optimised system to provide a rapid release multiparticulate formulation. Lornoxicam 
systems were prepared through co-evaporation with either PEG or Pluronic® F-68 and 
adsorption onto Neusilin® US2 alone or co-adsorption in the presence of different amounts 
of polysorbate 80. All systems were characterised by FT-IR, DSC, XRD, flowability and 
dissolution techniques. Mini-tablets were prepared using the system with the optimum 
dissolution profile and flowability. Tensile strengths, content uniformity and dissolution 
profiles of the mini-tablets were evaluated.  The effects of different excipients and storage 
conditions on mini-tablet properties were also studied. The optimised rapid release 
lornoxicam mini-tablets were further evaluated for their in-vivo pharmacokinetic profile.  
The co-evaporate of lornoxicam with Pluronic® F-68 showed significantly faster dissolution 
and superior flowability and was evaluated together with three directly compressible 
excipients (Cellactose® 80, StarLac® and Emcompress®) for mini-tablet formulation. The 
formulation with StarLac® provided the optimum results in terms of tensile strength, 
content uniformity and rapid drug release following a 3 month stability study and was 
selected for further in vivo evaluation. The pharmacokinetic profile indicated the potential 
of the mini-tablets achieving rapid release and increased absorption of lornoxicam.   
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Abbreviations 
LOR – Lornoxicam  
PEG – Polyethylene glycol 6000 
PLU – Pluronic® F-68  
NEU – NEU® US2  
CEL – Cellactose® 80 
STA – StarLac® 
DCP – Emcompress® 
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Introduction 
Lornoxicam (LOR) is a non-steroidal anti-inflammatory drug (NSAID), with analgesic and anti-
pyretic properties1 and although structurally related to piroxicam and tenoxicam, LOR is ten-
fold more potent2. Because LOR is used to treat patients with rheumatoid arthritis, 
osteoarthritis and postoperative management of pain associated with orthopaedic, 
abdominal, and dental surgeries1,3,4 a rapid onset of action is a desired attribute, but LOR 
has limited solubility in gastric media which is a rate limiting step for rapid absorption5. 
Several techniques have been investigated to enhance the dissolution of poorly soluble 
compounds, such as; micronization6, formation of inclusion complexes with cyclodextrins7-9, 
micellar solubilisation10,11 and solid dispersions with hydrophilic macromolecules12-14. 
Additionally, adsorption onto compounds with a high surface area (e.g. silicates) can be 
used successfully to enhance the dissolution and hence the bioavailability of drugs 15-18.  
 
Mini-tablets are compact dosage forms 1.5 - 4 mm in diameter19 that can be produced by 
conventional methods, using ordinary reciprocating and rotary tableting machines20. Mini-
tablets can provide dose accuracy, whilst overcoming the stability and storage problems 
associated with liquid formulations and the swallowing difficulties associated with 
conventional tablets, which may be encountered by some patients21.  Mini-tablets, like 
other multiparticulate systems, also offer the advantage of ease of dose adjustment by 
altering the number of units administered without the need for any formulation or process 
change22. Furthermore, because of their uniform size and shape, smooth surface, low 
porosity and high strength, mini-tablets can maintain their structure and shape in a more 
reproducible way than other multiparticulate dosage forms such as pellets and granules23.  
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The aim of this work was to enhance the dissolution of LOR in gastric media through solid 
dispersion with polyethylene glycol 6000 (PEG) as an example of a hydrophilic 
macromolecule, Pluronic® F-68 (PLU) as a non-ionic surfactant and adsorption onto the 
surface of Neusilin® US2 (NEU), a synthetic amorphous form of magnesium 
aluminometasilicate. Furthermore, the effect of co-adsorption of LOR onto the surface of 
NEU in the presence of different amounts of polysorbate 80 was also studied. The LOR 
systems which showed the optimum dissolution profiles were selected for further 
characterization and formulation into mini-tablets. Moreover, the effect of different directly 
compressible excipients on the mechanical properties and in-vitro release of LOR mini-
tablets was studied and the stability of the mini-tablets under different storage conditions 
was evaluated. An in vivo study was also performed in rabbits to estimate the 
pharmacokinetic parameters for the optimised mini-tablet formulation and to calculate the 
absolute bioavailability in comparison to intravenous delivery of LOR. 
 
Materials and methods: 
LOR was kindly provided by Delta Pharma, (10th of Ramadan City, Cairo, Egypt). PEG was 
obtained from BDH laboratory suppliers, England. PLU was obtained from BASF, SE 
Ludwigshafen, Germany. NEU was supplied from Fuji Chemical Industry, Japan. Cellactose® 
80 (CEL) and StarLac® (STA), co-processed directly compressible excipients comprising 75% 
α-lactose monohydrate: 25% cellulose and 85% α-lactose monohydrate: 15% corn starch 
respectively, were received from Meggle BG excipients and technology, Germany. 
Emcompress® (DCP), Calcium Hydrogen Phosphate Dihydrate, was obtained from JRS 
Pharma, Germany. All solvents used in HPLC analysis were of HPLC grade, (Merck, 
Darmstadt, Germany). All other chemical and analytical reagents were of analytical grades 
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and used as received. 
Preparations of LOR solid dispersions and co-adsorbate systems 
Solid dispersions of LOR with PEG, PLU and NEU were prepared by a solvent evaporation 
technique in order to enhance the dissolution of LOR in gastric fluids. Different weight ratios 
of LOR: carriers (1:1, 1:3 and 1:5) were prepared. Briefly; accurately weighed amounts from 
LOR and the investigated carriers were dissolved in chloroform. The solvent was allowed to 
evaporate in room temperature using magnetic stirrer. After solvent evaporation the 
powdered mass was dried in vacuum oven at 40°C until a constant weight was reached, 
ground gently in a mortar using a pestle and the particle size fraction < 200µm was collected 
through sieving. Powder samples were stored in desiccator for further analysis. 
Furthermore, co-adsorbate systems of LOR onto the surface of NEU with different amounts 
of polysorbate 80 in the ratios 1:5:1 and 1:5:3 (LOR: NEU: polysorbate 80) were also 
prepared using the solvent evaporation technique. Polysorbate 80 was dissolved in 
chloroform before the calculated amounts of LOR and NEU were added. Powders were 
collected, dried, sieved and stored in desiccator as previously described. Physical mixtures 
of LOR with the different carriers were prepared with the same weight ratio for 
comparisons. A control sample of LOR prepared via solvent evaporation in the absence of 
any additives was also prepared. 
 
Physicochemical characterisation of LOR systems 
FT-IR spectra, DSC thermograms and X-ray diffractograms were recorded for pure LOR, 
PEG, PLU, NEU and their solid systems in the weight ratio of 1:5. 
 
Fourier-transform infrared spectroscopy 
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The spectra were obtained using a Perkin Elmer Spectrum BX Spectrometer, England, fitted 
with a PIKE technologies MIRacle sampling accessory and using Spectrum v5.0.1 for data 
processing. The produced spectrum was an average of 16 scans and performed in the 
scanning range of 4000–550 cm−1 at ambient temperature. 
 
Differential scanning calorimetry 
Differential scanning calorimetry (DSC) thermograms were obtained using a Perkin Elmer 
DSC 8000 with Intracooler 2 cooling accessory and Pyris v. 10.1.0.0420 software (Seer 
Green, UK). The furnace temperature was calibrated using the Perkin Elmer supplied 
standard reference materials Indium (m.p. = 156.60 °C) and zinc (m.p. = 419.47 °C). Samples, 
3-5 mg, were accurately weighed onto aluminum pans and sealed prior to heating at a 
constant heat rate of 20°C min-1 in a nitrogen atmosphere over a temperature range of 25–
250°C. 
 
Powder X-ray diffraction 
Powder X-ray diffraction (PXRD) patterns were collected by using a Rigaku Miniflex X-ray  
diffractometer. Samples were finely ground and packed into an aluminum sample holder.  
Patterns were collected between 5° and 50° 2θ, at increments of 0.02° 2θ, scanning speed 
2°min-1, voltage 30KV, current 15 mA using CuKα (1.54 Ǻ) radiation. 
 
Powder density 
The bulk and tapped density properties of the optimum LOR systems in terms of superior 
dissolution, LOR/PLU co-evaporate (1:5 weight ratio) and LOR/NEU/polysorbate 80 co-
adsorbate (1:5:3 weight ratio), were determined. Bulk density (ρB) was calculated by 
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measuring the volume of a known weight of powder mixture in a measuring cylinder. 
Tapped density (ρT) was calculated using the volume of the powder after tapping the 
cylinder 200-250 times, after which there was no further reduction in the volume of 
powder. Carr’s compressibility index (CI) values and Hausner ratios were determined 
according to equation 1 and equation 2 respectively.  
 
                Carr’s Index (%)   =   
𝜌𝑇−𝜌𝐵
𝜌𝑇
   𝑥 100                                             Equation 1 
 
                Hausner Ratio   =   
𝜌𝑇
𝜌𝐵
                                                                  Equation 2 
 
Powder mixing 
LOR/PLU co-evaporate mixture (1:5 weight ratio) was mixed with an equal amount of a 
directly compressible excipient (either CEL, STA or DCP) using a turbula mixer (W.A. 
Bachofen, Switzerland) for 15 min  and subsequently with 1 %w/w magnesium stearate for 
5 min. The powder flowability of the formulations was assessed as previously described.    
 
Production and testing of LOR mini-tablets  
Formulations were compressed into mini-tablets over a range of compression pressures 
using a Stylcam® 100R rotary press simulator (Medel’Pharm, France) fitted with flat-faced 3 
mm tooling at a speed of 20 rpm.  Mini-tablet thickness, T (mm) and diameter, D (mm) were 
measured using a micrometer (Mitutoyo, Japan). Crushing strengths, F (N), were 
determined using a model 6D tablet tester (Dr. Schleuniger, Germany) and tensile strengths, 
σt,  (MPa) were calculated according to Equation 3 
24. 
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                                     σt= 2F/πDT                                                      Equation 3. 
Compression profiles (pressure vs. strength) were used to characterise each of the LOR 
mini-tablet formulations and subsequent mini-tablets were produced at compression 
pressures of 200 – 300 MPa for in-vitro dissolution, content uniformity, stability testing and 
in vivo studies. 
 
Lornoxicam content 
The drug content of LOR from 10 randomly selected mini-tablets in each batch was 
determined. Briefly, each mini-tablet was grinded, dissolved in 50 mL acetone/PBS 7.4 and 
filtered (Whatman grade 1 filter paper, 11 μm, (Ø 70 mm), GE Healthcare Life Sciences, UK). 
Filter compatibility was verified by passing a standard solution of LOR through the filter and 
determining the concentration of the filtrate.  LOR contents were determined as a 
percentage for each unit using UV/VIS spectrophotometer (Lambda 40, Perkin Elmer, UK) at 
λmax of 372nm run via the UV WinLab version 2.80.03 software. The acceptance value (AV) 
was then calculated according to USP Pharmacopeia 36 (2013) using Equation 4. 
                            AV = │M+X¯│+ ks                                                                Equation 4 
Where M is a reference value; X¯ is a mean of individual contents expressed as a percentage 
of label claim; k is the acceptability constant (if n = 10, it will be equal to 2.4) and s is the 
sample standard deviation. 
In-vitro dissolution 
Dissolution tests on the LOR powder samples and mini-tablets were performed in 0.1 N HCl, 
(pH 1.2) at 37 ± 0.5 °C using an automated Varian VK 7000 dissolution tester and a Cary 50 
UV spectrophotometer at λmax of 372 nm. Samples (5 mL) were removed from the 
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dissolution vessels through full flow 35 μm filters (Agilent Technologies, USA) at specified 
time points and recirculated via peristalitic pump. An additional dissolution test was 
performed on the LOR/NEU adsorbate (1:5 weight ratio) sample in 0.1 N HCl media 
containing 12 mg polysorbate 80 to evaluate the effects of the surfactant in drug 
solubilisation. 
 
Stability study 
LOR mini-tablets were stored in open amber glass containers at in desiccators at room 
temperature / 75% RH (saturated solution of NaCl) or 45% RH (saturated solution of 
K2CO3.2H2O), 40°C/75% RH and at ambient temperature and humidity conditions for 3 
months25,26. After the stated time mini-tablets were evaluated for their LOR content, tensile 
strength and in-vitro release. The method for LOR quantification using UV 
spectrophotometry was validated according to ICH guidelines on Validation of 
Analytical Procedures27. The wavelength corresponding to the maximum absorbance in PBS 
of pH 7.4 and 0.1N HCl was found to be 372 nm. Beer's law obeyed over the concentration 
range of 2-20 μg/mL with correlation coefficient (r2) value of 0.9997 and 0.9992 for PBS of 
pH 7.4 and 0.1 N HCl, respectively. Intra-day and inter-day precision (%RSD) at different 
concentration levels were < 2%, indicating that the proposed spectrophotometric method is 
highly reproducible during one run and between different runs and can be adopted for 
determination of LOR in mini-tablet formulations. LOD and LOQ were 0.175 and 0.380 
μg/mL, respectively in both media signifying the sensitivity of the method. Moreover, the 
mean recovery was ranged from 99.55% - 100.25%, indicating the accuracy of the method. 
Also, the obtained results of LOR assay in the presence of different carriers and excipients 
was found to be in agreement with the label claim indicating absence of interference with 
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the excipients. The reliability study showed lower value for %RSD at p<0.05 indicating no 
significant difference between the two UV spectrophotometric instruments used. 
In-vivo study and pharmacokinetic analysis 
An In-vivo study was performed to determine the pharmacokinetics of LOR from mini-
tablets produced with the optimal formulation in terms of in-vitro release and stability. 
Furthermore, the absolute bioavailability of LOR in comparison to an aqueous intravenous 
(IV) injection was estimated. This was performed through administration of single equal 
doses, 0.75 mg kg-1, of mini-tablet and IV injection to male New Zealand rabbits (2.0-2.5 Kg) 
using non-blind, two treatment design. Doses were calculated from typical human LOR dose 
and body surface area in comparison to rabbit. The protocol of the study was approved by 
the research Ethics Committee in the Faculty of Medicine, Assiut University, Egypt.  
 
Study design and chromatographic conditions 
Six male rabbits were randomly distributed into two groups of equal numbers. The animals 
were kept in individual cages under well-defined and standardized conditions (humidity and 
temperature controlled room) and fed with standard food and water access. Furthermore, 
the rabbits were cannulated in the right jugular vein prior to study day and allowed to 
recover and fast overnight for 12 h28. On the study day, each rabbit in the first group 
received a LOR mini-tablet (Treatment A). The tablets were placed gently into the mouth of 
the rabbits and swallowed with the aid of water. Rabbits of the second group received equal 
doses of LOR through intravenous injection of Xefo® vial, October Pharm, Egypt (Treatment 
B). Blood samples (250 µL) were collected immediately after administration of LOR injection 
in the second group. Moreover, blood samples were also collected at scheduled time 
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intervals (0.5, 1, 2, 4, 8 and 24 h) from both treatments and treated with heparin to prevent 
blood clotting. The plasma were obtained via centrifugation (3500 g) for 10 min (Centurion 
Scientific Ltd, UK), kept in glass tubes and then deep frozen at -25°C. Prior to HPLC analysis, 
aliquots of plasma (100 µL) or the calibration standards (100 µL of an internal standard 
solution of piroxicam, 5 µg ml-1) and 100 µL of 5M HCl were added to a glass tube. After 
brief vortex mixing (Maxi Mix, Thermolyne, USA) 5 ml of diethyl ether was added and the 
mixture was vortex mixed for 30 s. Each sample was centrifuged (2500 rpm for 10 min), and 
the organic layer was transferred to a new glass tube and evaporated to dryness under a 
gentle stream of nitrogen at 40°C. The residue was reconstituted with 500 µL of the mobile 
phase, (mixture of 20 mM potassium monophosphate-acetonitrile 60:40 v/v, adjusted to pH 
3.5 with ortho-phosphoric acid, at a flow rate of 1.2 mL min-1), filtered (0.45 μm glass 
microfiber/nylon membrane filter (Ø 25 mm), Agilent technologies, USA) and a 20 µL aliquot 
was injected into the HPLC system. The HPLC system, Knauer, Germany consisted of HPLC 
pump (Knauer D – 14163), UV- detector (Knauer, D – 14163), and integration interface box 
(Knauer, D – 14163). Chromatographic separation was carried out using Kromasil C-18 
column (250 x 4.60 mm, particle size: 10 μm).  
 
Method validation 
The method was validated according to ICH guidelines on Validation of Analytical  
Procedures27. The detection wavelength, 377 nm, was determined by scanning the 
maximum absorbance wavelength of LOR and piroxicam in the mobile phase using a UV 
spectrophotometer (Jenway, Model 6305, UK). The specificity of the method was 
determined by analysing 15 different blank rabbit plasma samples, to demonstrate lack of 
chromatographic interference from endogenous plasma components at the retention time 
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of both LOR and the internal standard. No significant interfering peak from plasma 
endogenous compounds was observed at the retention times of LOR and the internal 
standard which were 3.9 min and 7.8 min respectively. The limit of detection (LOD) and 
lower limit of quantitation (LLOQ) were determined from the ratio of peak signal and 
baseline noise and were 40 ng/mL and 50 ng/mL respectively for this method. The linearity 
of the calibration curve for LOR was assessed over the range of 50 to 3000 ng/mL and was 
performed after subjecting plasma samples to the sample preparation procedure followed 
by injection onto the HPLC system. Moreover, the stability of LOR in plasma was studied in 
three different conditions: frozen plasma (-70.0 ±2.0°C) was kept at room temperature for 6 
h before sample preparation (short term stability), freezer stability at -70.0 ±2.0°C for 30 
days (long term stability) and three freeze-thaw cycles (stored at -70.0 ±2.0°C between 
cycles) using QC samples spiked with LOR at low (50 ng/mL) and high (1800 ng/mL) 
concentrations.  A standard curve was constructed by plotting the peak area ratios of LOR 
and piroxicam against LOR concentrations in plasma. Results were fitted to linear regression 
analysis. Six replicates of calibration curve were prepared taking each concentration for six 
times. The regression coefficient (R2) value was used to evaluate the linearity of the 
calibration curve. The standard curves of LOR in rabbit plasma were linear with a reliable 
reproducibility over the ranges of 50 to 3000 ng/mL and the regression coefficients (R2) 
were over 0.9992 from each standard curve of six separate runs. The accuracy and precision 
was confirmed by analysing six replicates at three QC levels (low, medium and high) and 
LLOQ on four different days. The intra-day and inter-day accuracy of this bioanalytical 
method, expressed as the relative standard error, was from 96.22 ±22.3% to 99.72 ±15.4% 
and from 96.06 ±11.2% to 99.10 ±13.5% respectively for LOR concentration from 50 to 3000 
ng/mL. Furthermore, the intra-day and inter-day coefficient of variation ranged from 1.310 
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±0.22% to 3.215 ±0.87% and from 1.011 ±0.32% to 3.046 ±0.65% respectively. The data 
confirmed the satisfactory accuracy, precision and reproducibility of the method. Also, it 
was found that thawing the frozen samples and keeping them at room temperature for 6 h 
had no effect on quantiﬁcation and the quality control samples stored at −70°C remained 
stable for 1 month. Furthermore, the three freeze–thaw cycles of the quality control 
samples did not appear to affect the quantiﬁcation, suggesting that human plasma samples 
containing LOR can be handled under normal laboratory conditions without any signiﬁcant 
loss of compound. 
Pharmacokinetic analysis 
The residual method was adapted to estimate the pharmacokinetic parameters of the two 
treatments for each subject. The maximum drug concentration (Cmax, µg mL
-1), the time to 
reach Cmax (Tmax, h), the absorption rate constant (K, h
-1), the absorption half-life (t1/2a, h), 
the elimination rate constant (Ke, h
-1), elimination half-life (t1/2e, h) as well as the mean 
residence time (MRT(0-∞), h) were obtained from the LOR plasma concentration time curves. 
The trapezoidal rule method was employed to calculate the area under curve from zero to 
24 hr (AUC(0-24), µg.h/ml)
29. Moreover, the area under curve from zero to infinity (AUC(0-∞), 
µg.h ml-1) was calculated using Equation 530 and the absolute bioavailability (%) was 
calculated using Equation 6.  
 
AUC(0-∞) = AUC(0-t) + Ct / Ke                                                                                                           Equation  5 
Where Ct is the drug plasma concentration observed at time t, Ke is the apparent elimination 
rate constant.  
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Absolute bioavailability (%) =     
𝐴𝑈𝐶 (0−∞) 𝑚𝑖𝑛𝑖−𝑡𝑎𝑏𝑙𝑒𝑡
𝐴𝑈𝐶 (0−∞) 𝐼𝑉 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛
  X 100                 Equation  6 
Statistical analysis 
Data were presented as mean ± SD. The linearity of the calibration curve for LOR was 
validated using the coefficient of determination R2. LOR release, mini-tablet tensile strength 
and pharmacokinetic data were compared by one-way analysis of variance and post-hoc 
Tuckey’s test using the Minitab 16 statistical software package (Minitab Inc., USA). A P value 
of less than 0.05 was considered to be significant. 
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Results and Discussion 
The aim of this study was to enhance the dissolution of LOR in gastric fluids followed by 
formulation into mini-tablets with the potential to rapidly deliver LOR, providing dose 
flexibility for patients with swallowing difficulties. 
 
Physicochemical characterisation of LOR solid dispersions and co-adsorbate systems 
 
Fourier-Transform Infrared spectroscopy 
Figure 1 represents the FT-IR spectra of pure LOR, PEG, PLU, NEU and their physical 
mixtures, co-evaporate, adsorbate and co-adsorbate systems. LOR showed a characteristic 
peak at 3065 cm−1 corresponding to –NH stretching vibration. The stretching vibration of 
carbonyl group in the primary amide showed intense absorption peak 1644 cm−1. Other 
peaks were observed at 1591 and at 1531 cm−1 and were assigned to bending vibrations of 
N-H group in the secondary amide. Sulphonyl group showed stretching vibrations bands 
appeared at 1143, 1379, and at 1323 cm−1. Other prominent peaks appeared at 828.25 cm−1 
corresponding to -CH aromatic ring bending and heteroaromatics and at 788.22 cm−1 
assigned for C-Cl bending vibration. On the other hand, PEG and PLU have nearly the same 
FT-IR spectrum with absorption bands at 3400 cm-1 O-H stretching vibration, C-O stretching 
at 1110 cm-1 and 2882 cm-1 C-H stretching vibration31. NEU showed a shallow peak from 
3100 to 3600 cm-1 which can be attributed to the bound water molecules. Physical mixtures 
of LOR and the investigated carriers showed the same characteristic peaks of LOR at the 
same positions at the different prepared weight ratios and thus give indication about the 
absence of any interaction in physical mixture. However, in co-evaporate, adsorbate and co-
adsorbate systems a complete disappearance of the –NH stretching vibration was observed 
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at 1:3 and 1:5 weight ratio of the carrier concomitant with appearance of the other LOR 
peaks but they are reduced in their intensities. In case of co-evaporate of LOR with PEG and 
Pluronic® (1:5 weight ratio) there was a slight shift in sulphonyl group stretching vibrations 
to 1146 and 1340 cm-1. Similarly, with NEU adsorbates mixtures (1:3 and 1:5 weight ratio) 
the sulphonyl group stretching vibrations were shifted to 1335 and 1429 cm-1 and the C-Cl 
bending vibration was highly reduced in its intensity. Furthermore, co-adsorbate systems 
displayed a shift of sulphonyl group stretching vibrations to 1431 and 1346 cm-1 and 
complete disappearance of C-Cl bending vibration. Moreover, the stretching vibration 
appeared at 2925 cm-1 assigned for –CH2 groups of polysorbate 80 becomes clearer at a 
higher ratio of polysorbate 80 (1:5:3 weight ratio systems, Fig.1, trace K) and the shallow 
peak at 3390cm-1 becomes broader due to interaction with the –OH stretching vibration of 
polysorbate 80. This FT-IR data referred to the formation of intermolecular hydrogen bond 
between the -NH group of LOR and –OH group of PLU and PEG or Si of SiO2; respectively 
especially in higher carrier ratios 1:3 and 1:5. The formation of hydrogen bonds between 
oxicams and PEG 400032 or Poloxamer 18833 has also been reported. At the same time, the 
interaction between LOR and NEU could be attributed to an acid-base interaction as LOR is a 
weak acid and NEU is a basic compound. Similarly, the interaction between Acclofenac and 
NEU was found to be an acid-base reaction18.  
 
Differential scanning calorimetry 
The DSC thermograms of pure LOR, PEG, PLU, NEU and their physical mixtures, co-
evaporate, adsorbate and co-adsorbate systems are presented in Figure 2. LOR exhibited a 
single sharp exothermic melting peak at 232.9°C, which is probably due to drug melting and 
decomposition34. No difference was observed in the DSC thermograms for pure LOR and the 
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control sample of LOR prepared via solvent evaporation alone (data not shown) confirming 
the absence of any solvent-mediated conversions. The DSC thermograms of PEG and PLU 
showed a melting endotherm at 56°C and 62°C, respectively. Furthermore, NEU did not 
show any melting endotherm over the temperature range studied probably due to the 
amorphous nature of this carrier18. The LOR melting exotherm was completely absent from 
the investigated physical mixtures and solid dispersion (co-evaporate systems) with either 
PEG or PLU. In the case of the physical mixture, this behaviour could be possibly attributed 
to the dilution effect of the carrier, especially when present at a high ratio in these samples 
(1:5 weight ratio), and/or melting of the carrier at a lower temperature causing dissolution 
of drug crystals in the molten mass of the carrier and the formation of amorphous LOR 
during the DSC scan. Similar observations have previously been reported35-38. However, in 
the case of the co-evaporate systems with both PEG and PLU, the disappearance of LOR 
melting exotherm may be due to the interaction between the drug and the carrier as 
pointed out from the FT-IR study and thus suggesting possible conversion of crystalline LOR 
to an amorphous structure within the carrier matrix. Similar behavior was also observed in 
case of NEU physical mixtures, adsorbates and co-adsorbates. However, the absence of LOR 
peak in physical mixture could be attributed to the dilution effect (1:5 weight ratio) and 
interaction between LOR and NEU at the molecular level in case of adsorbate and co-
adsorbate systems as observed from FT-IR study. The above finding suggested that the 
solvent evaporation method induces a certain type of interaction between LOR and the 
investigated carriers at the molecular level. Similar results were also reported for LOR solid 
dispersion formation using PVP K30 through solvent evaporation technique39 and co-ground 
mixture of Acceclofenac with NEU18. To gain further information and evidence about the 
conversion of LOR from crystalline to amorphous state XRD study was conducted.   
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X-ray powder diffractometry 
X-ray powder diffraction patterns of pure LOR, PEG, PLU, NEU and their physical mixtures, 
co-evaporate, adsorbate and co-adsorbate systems are depicted in Figure 3. LOR showed 
several sharp high intensity peaks at diffraction angles 2θ of 7.8°, 10.2°, 12.96°, 13.78°, 
18.85°, 21.84, 22.87°, 24.6°, 25.35°, 26.90°, 27.95° and 30.44° suggesting its crystalline 
nature. No difference was observed in the X-ray powder diffraction patterns for pure LOR 
and the control sample of LOR prepared via solvent evaporation alone (data not shown) 
confirming the absence of any solvent-mediated conversions.  PEG has two characteristic 
peaks at 2θ values of 19.11° and 23.19° 40. PLU was also in the crystalline form, having two 
distinct peaks at 2θ values of 19.18° and 23.21° and a relative broad peak with low intensity 
between 24° to 27° 2θ 41. NEU did not show any crystalline peaks, confirming it is an 
amorphous compound 18. It was found that physical mixture of the drug with PEG, PLU or 
NEU showed the characteristic peaks of LOR but they were far lower in their intensity due to 
the dilution effect of the carrier. This finding revealed that LOR was present in a crystalline 
state, as evidenced by its diffraction lines, and thereby ruled out the existence of drug–
carrier interaction in the physical mixtures. Furthermore, some LOR diffraction peaks were 
absent from the co-evaporate systems with both carriers while the intense LOR peaks were 
still detected (Fig. 3). This demonstrated the presence of LOR in ultrafine crystallites within 
the carrier matrix and is in accordance with previous reports where the interaction between 
LOR and PVP K30 in a physical mixture and co-evaporate system was studied39. Moreover, 
the diffraction peaks of PLU at 19.1°, 23.3°, and 26° 2θ could still be observed, suggesting 
that PLU was still present in the crystalline form in both physical mixtures and co-evaporate. 
This attributed to the presence of PLU in its crystalline state even after recrystallization 
during solvent removal in the co-evaporation process41. On the other hand, the LOR 
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diffractograms in adsorbates (1:5 weight ratio) and co-adsorbates (1:5:3 weight ratio) 
showed a complete absence of LOR crystalline peaks. This observation indicates that LOR 
was entirely converted to the amorphous form. However, the co-adsorbate system (1:5:1 
weight ratio) still showed minute LOR diffraction peaks indicating the presence of LOR in a 
microcrystalline form. So, from the PXRD study, it was clear that LOR physical mixtures with 
the investigated carriers were still crystalline and the disappearance of LOR melting 
exotherm observed in DSC was completely due to melting of LOR in the molten mass of the 
carrier and/or the dilution effect. Furthermore, LOR was present in ultrafine crystallites in 
the co-evaporate mixture with PEG and PLU despite the complete disappearance of the LOR 
melting exotherm. Additionally, the complete amorphization of LOR in adsorbate (1:5 
weight ratio) and co-adsorbate (1:5:3 weight ratio) systems supported the results of DSC 
analysis and revealed that adsorption onto the surface of NEU and co-adsorption in the 
presence of polysorbate 80 can be used successfully to obtain amorphous LOR. It is worth 
noting that after 3 months refrigerated storage, XRD studies for the LOR PLU co-evaporate 
and the LOR co-adsorbate (1:5:3 weight ratio) systems were repeated and found to be 
unchanged in comparison to fresh samples.  
 
In-vitro dissolution  
Figure 4 shows the dissolution profiles of LOR alone, physical mixtures, co-evaporate, 
adsorbate (1:5 weight ratio) and co-adsorbate systems (1:5:1 and 1:5:3 weight ratio). It was 
clearly evident that LOR dissolved very slowly under the specified dissolution conditions and 
less than 12 ±1.5% of LOR was dissolved after 1 h in gastric pH conditions. No difference was 
observed in the dissolution pure LOR and the control sample of LOR prepared via solvent 
evaporation alone (data not shown) confirming the absence of any solvent-mediated 
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conversions.  However, it was apparent that LOR dissolution was significantly (P < 0.05) 
improved when physically mixed with the carriers in the order: PLU > NEU > PEG, (38.8 ±1.8 
> 35.4 ±1.7 > 28.2 ±0.4%) respectively. Moreover, increasing the amount of carrier from 1:1 
to 1:5 weight ratios in all of the investigated systems led to enhancement of LOR 
dissolution. In the case of the co-evaporate mixtures, PLU showed a significantly (P < 0.05) 
higher rate and extent of LOR dissolution after 1 h (90.3 ±1.9%) followed by PEG (63.2 
±0.7%) and finally NEU (40.2 ±0.8%). On the other hand, co-adsorbates with higher amounts 
of polysorbate 80 (1:5:3 weight ratios) showed almost 100% LOR dissolved after 15 min 
compared with 63.3 ±0.4% and 27.1 ±0.2% LOR dissolved from the co-adsorbate (1:5:1 
weight ratio) and adsorbate mixture respectively. The slight enhancement of LOR 
dissolution in the case of the physical mixtures with different carriers could be attributed to 
the decrease in LOR crystallinity and or the effect of carriers. PEG is a hydrophilic carrier and 
can impart a local solubilisation action in the diffusion layer surrounding the drug particles 
and increase the drug wettability and subsequent dissolution42,43. Furthermore, PLU is a 
non-ionic surfactant and can form micelles to aid drug solubilisation44. However, the 
significantly higher (P < 0.05) dissolution of LOR from co-evaporate mixtures with either PEG 
or PLU compared with physical mixtures and pure LOR were due to the presence of LOR in a 
molecular dispersion form within the carrier. Additionally, LOR was present in ultrafine 
crystals with a larger surface area available for dissolution as confirmed from the DSC and 
XRD studies. NEU is an inert amorphous material consisting of spray-dried agglomerates of 
magnesium aluminosilicate15, Furthermore, NEU has a high speciﬁc surface area (~280 m2/g) 
and a high adsorption capacity (~3.2 mL/g) making it a good core material for adsorption of 
a high proportion of drugs15. LOR adsorption onto the surface of NEU, as well as the 
formation of intermolecular hydrogen bonding between the –NH group of LOR and Si of SiO2 
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groups of NEU concomitant with conversion of LOR into an amorphous state were 
responsible for the enhancement of LOR dissolution. As the proportion of NEU increases 
from 1:1 to 1:5 weight ratio, the effective surface area over which the drug is spread 
increases accompanied by an enhancement in drug dissolution. Similar results have been 
presented elsewhere15,18 and it has also been reported that the dissolution rate of both 
meloxicam and piroxicam were enhanced through adsorption onto the surface of Florite® 
and microcrystalline cellulose45,46. It is also worth noting that the co-evaporate system with 
either PEG or PLU gave significantly (P < 0.05) higher percentage of LOR dissolved compared 
with LOR adsorbate. This could possibly be attributed to the higher amounts and large 
specific surface area of NEU as it has been stated that the adsorbent having the larger 
surface is considered to show the lower dissolution rate47,48. Polysorbate 80 is a non-ionic 
surfactant and mainly used to enhance the solubility and dissolution of many water 
insoluble compounds11. LOR co-adsorbate onto NEU in the presence of polysorbate 80 has 
the ability to give a significant very rapid dissolution. The enhancement of LOR dissolution 
could be attributed to two different mechanisms; drug solubilisation within the polysorbate 
micellar core, followed by adsorption onto the surface of NEU. Similar results were reported 
for enhancement the dissolution of celecoxib using Florite® and polysorbate 80 at the ratio 
of 1:5:3 (celecoxib: Florite®: polysorbate 80)49. Also, it was reported by other researchers 
that adsorption of gentamicin and lanzoprazole onto the surface of different adsorbents and 
in the presence of different types of non-ionic surfactants can enhance the dissolution rate 
and the oral bioavailability of such drugs 47,48. When the dissolution of the LOR/NEU 
adsorbate (5:1 weigh ratio) was evaluated in media containing additional polysorbate 80 in 
order to further evaluate the surfactant effects, the amount of LOR dissolved after 1 h 
increased to 68.5 ±3.5% (data not shown) from the previous value of 40.2 ±0.8% in the 
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absence of polysorbate 80. This demonstrated that the presence of polysorbate 80 did 
enhance the dissolution of LOR through prevention of recrystallization and wetting, but also 
confirmed the benefit of the co-adsorbate system, where the drug is initially solubilised by 
the aid of surfactant followed by adsorption into the large surface area of NEU to form ultra-
fine deposits. The solubilised drug subsequently dissociates from the surface of NEU on 
contact with the dissolution media and dissolves rapidly. 
 
Powder density  
The Carr’s Index and Hausner Ratio values of the two optimum LOR systems and the 
subsequent formulations with directly compressible excipients are presented in Table 1. The 
LOR co-adsorbate system displayed very high Carr’s Index values compared with LOR co-
evaporate mixture with PLU, which demonstrated far superior flow characteristics. The 
higher Hausner Ratio of the co-adsorbate formulation also indicated a greater degree of 
interparticle friction. Although, NEU has good flow and compressibility properties, the 
addition of polysorbate 80, especially at a higher ratio, is likely to have led to more adhesion 
and stickiness between the particles which could be responsible for the poor flowability. As 
the need for improved flowability is exacerbated when manufacturing mini-tablets due to 
the narrow die orifice, the co-adsorbate system with NEU and polysorbate 80 was not 
considered for further evaluation in this study, whilst the co-evaporate system with PLU was 
assessed for its suitability in the formulation of rapid release LOR mini-tablets. Blending of 
the LOR/PLU co-evaporate system with directly compressible excipients led to a marked 
reduction in Carr’s index and Hausner ratio (Table 1). The formulation with STA showed 
superior flowability and the effect of enhancing the powder flow of the LOR/PLU co-
evaporate system can be ranked in the following order STA > DCP > CEL. 
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Characterisation of LOR mini-tablets 
The mini-tablets manufactured were uniform in their weight (18 ± 1 mg) and thickness (2 ± 
0.1 mm) providing a LOR dose of 1.5 ± 0.1 mg per mini-tablet. The prepared LOR mini-
tablets complied with US Pharmacopeia 36 requirements in terms of uniformity of drug 
content, (case I, in which target content per dosage unit (T) < 101.5% can be applied) as the 
(AV) value for all formulation tested < L1 (%) = 15. 
 
Figure 5 shows the compression profiles for the mini-tablet formulations. Mini-tablets 
manufactured with all formulations displayed acceptable tensile strengths over a range of 
compression pressures.  Although  mini-tablets comprising CEL and DCP displayed superior 
compression profiles compared to the STA formulation at lower compression pressures, 
more comparable tensile strength values in the range were obtained at higher compression 
pressures > 300 MPa.  The higher strengths displayed by the mini-tablets comprising CEL at 
even low compression pressures (~ 100 MPa) is attributable to the compactibility of the 
excipient. CEL is a co-processed, spray-dried compound formed from 75% α-lactose 
monohydrate: 25% cellulose and combines the ideal filler and binder properties of its two 
ingredients, which consolidate by synergistic fragmentation and plastic deformation 
mechanisms respectively50. STA is a co-processed filler-binder consisting of 85% α-lactose 
monohydrate together with 15% corn starch51. The improved flowability and compressibility 
of STA in comparison to the equivalent physical mixtures of its components is due to the 
spray-drying process employed during processing52. At higher compression pressures (≥ 200 
MPa) the tensile strengths of the mini-tablets with CEL and DCP were comparable. DCP 
consists of aggregates of small primary particles of dicalcium phosphate and its binding 
properties are insensitive to production speed and the presence of lubricant due to the 
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mechanism of fragmentation during consolidation and compaction53,54.  
 
The dissolution profiles of the LOR mini-tablets at gastric pH are shown in Figure 6. The 
inclusion of STA and DCP successfully enhanced the extent of LOR released from mini-
tablets compared with CEL based formulations, by promoting rapid disintegration and 
subsequent dissolution. Mini-tablets with DCP provided 91 ±2.5% LOR release after 15 
minutes in comparison with the 99 ±0.7% release from those comprising STA (Fig 6). It is the 
presence of starch that imparts the rapid disintegration properties51 and leads to the very 
fast release of the active ingredient, which is the biggest advantage associated with STA52. 
On the other hand the rapid release from mini-tablets comprising DCP is associated with the 
rapid penetration of liquid into the mini-tablets due to the hydrophilic nature of the 
excipient53. The dissolution profile of mini-tablets with CEL on the other hand was 
significantly (p < 0.05) lower and provided < 40% LOR release after 15 min due to slow 
disintegration of the mini-tablets within the dissolution media. The structure of CEL means 
that cellulose disintegration only begins once the outer layer of lactose has dissolved, 
resulting in viscous aqueous solutions and further restricting water access to the cellulose 
nucleus55. The compactability of the different LOR/excipient blends may have also 
contributed to the differences in drug release, particularly as the mini-tablets comprising 
STA displayed generally lower tensile strengths in comparison to those comprising DCP and 
CEL over the 200 - 300 MPa range of compression pressures. Overall the rapid LOR release 
provided by mini-tablets produced with STA, coupled with the superior flowability, good 
tensile strength, weight and content uniformity would therefore provide optimal properties 
for further development. 
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Stability Studies 
Mini-tablets showed no significant decrease in LOR content after 3 months storage under 
ambient conditions or at RT/43% RH and RT/75% RH. But LOR content decreased to 92.6% 
(±4.8), 94.9% (±4.5) and 84.0% (±3.2) for CEL, DCP and STA respectively when stored at 
40°C/75% RH due to degradation of the drug. 
 
The fragility of all mini-tablets after 3 months storage at 40°C/75% RH due to the 
detrimental effects of the high temperature and humidity on their physical stability meant 
that tensile strength could not be determined. The strength of DCP and STA mini-tablets was 
slightly lower after 3 months storage at RT/43% RH and RT/75% RH due to the effects of 
moisture sorption (Table 2). Mini-tablets with CEL, however, increased in strength, probably 
due to the absorption of moisture leading to greater inter-particulate bonding within the 
mini-tablets. The hygroscopicity of cellulose powders is dependent on their structural 
properties, such as surface area, pore volume and crystallinity56 and moisture sorption 
during storage under humid conditions leads to water binding to the amorphous fibrils at 
the surface of microcrystalline cellulose particles57. The effects of increased moisture 
content on the compression properties of microcrystalline cellulose have previously been 
studied. It is recognised that whilst the low % of water tightly bound within the particles 
enhances interparticle bonding, higher levels of adsorbed moisture reduces tablet strength 
through plasticization of the particles58-60 and peak tensile strengths for microcrystalline 
cellulose compacts can exist at intermediate moisture contents61. Moisture sorption in CEL 
is much lower than microcrystalline cellulose alone because lactose covers the cellulose 
fibres as a result of the co-processing54. However, it appears that that sufficient post-
compression moisture sorption occurred within mini-tablets comprising CEL when stored at 
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higher % RH to enhance the interparticle bonding and tensile strength, which in all 
likelihood led to slower disintegration and further retardation of drug release. 
 
LOR release from mini-tablets with CEL decreased significantly (P < 0.05) after 3 months 
storage even at ambient conditions (Fig. 7). A decrease was also observed in the rate of LOR 
release from mini-tablets formulated with STA (81 ± 4.4% after 15 min) and more so with 
DCP (76 ± 2.5% after 15 min) following 3 months storage at ambient conditions. A more 
significant reduction in LOR release rate after storage at higher %RH and/or temperature 
was seen (Fig 8 & 9) due to the concomitant degradation of the drug.  Since no loss in LOR 
content was observed at ambient conditions, the reduction in drug release can be ascribed 
to physical changes within the mini-tablets upon exposure to atmospheric conditions over 
the 3 month period. It is likely that some recrystallization of LOR in the presence of the 
crystalline excipients within the mini-tablets resulted in the small reduction in release rate. 
The results indicate that appropriate packaging and storage conditions would be necessary 
to maintain the stability of the mini-tablets and to ensure that the dissolution enhancement 
of LOR achieved with the PLU co-evaporate system was maintained. Overall mini-tablets 
formulated with STA showed the most promising stability profiles, after 3 months storage 
and were further evaluated for in vivo performance. 
 
In Vivo study and Pharmacokinetic analysis 
The pharmacokinetic parameters of LOR following oral and intra-venous administration of 
single doses of 0.75 mg kg-1 of (A) mini-tablets and (B) IV injection into rabbits are shown in 
Table 3. Moreover, The LOR plasma – concentration time profiles of both treatments are 
depicted in Fig. 10 and could be best described by a one-compartment model with a first 
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order absorption and elimination for mini-tablets and a one-compartment IV-Bolus model 
with first-order elimination for IV injection. The peak plasma concentration of LOR was 
achieved after 2 h following administration of mini-tablets and the absolute bioavailability, 
calculated from the AUC(0-∞) for the oral mini-tablet compared to the IV treatment was 
found to be 93.90 ±3.9%.  A non-significantly higher peak plasma concentration (Cmax) was 
found with IV injection compared with mini-tablets (P > 0.05) and both treatments showed 
similar mean residence time (MRT) values. A significantly higher elimination half-life (t1/2e) 
was found for mini-tablets compared to IV injection, (P < 0.05). It is also worth noting that 
the absolute bioavailability and Cmax (93.90 ±3.9%  and 3.33 ±0.19 µg mL
-1 respectively) 
obtained for LOR mini-tablets in the present study are higher than the absolute 
bioavailability (80.1%) and Cmax (1.83 ±0.35 µg mL
-1) recorded previously from LOR 
suppositories62. Furthermore, the plasma concentrations after 0.5 h (1.5 ± 0.61 µg mL-1) and 
1 h (3.03 ±0.3 µg mL-1) and the Cmax achieved from 1.5 mg dose LOR mini-tablets are much 
higher in comparison to a 4 mg dose from conventional tablets63. LOR 8 mg twice daily is 
currently considered an effective and tolerable alternative NSAID for use as a sole agent or 
as part of multimodal analgesia in adults64 with some formulations providing pain relief after 
30 minutes65, whilst preoperative 16 mg LOR provides potent pain relief and prevents the 
need for postoperative rescue analgesia66. However, the increased absorption achieved 
from the lower dose mini-tablets in the present study could provide more dose flexibility 
and improved therapy for patients.  This improvement in absorption may be attributed to 
the enhancement in dissolution concomitant with the rapid disintegration of the mini-
tablets in gastric conditions. The time difference between the rapid dissolution and the Tmax 
is likely to be due to incomplete initial absorption of all the solubilized drug present in the 
gastric fluid due to ionization of the pyrindo group of LOR (pKa 5.5)5.  The high drug plasma 
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concentration obtained after 30 min and the high Cmax reached 2 hours post-dosing can be 
attributed to the higher lipophilicity of LOR (log P = 1.8)67. Additionally, the mean residence 
time of 7.414 ±0.48 h and the significantly (P < 0.05) longer elimination half-life of 8.115 
±0.99 h obtained with the mini-tablet formulation could be advantageous controlling the 
chronic pain associated with inflammatory conditions. Overall, the pharmacokinetic data 
indicate the potential of the mini-tablet formulation in achieving a high plasma 
concentration of LOR following rapid release from the dosage form, which could be 
beneficial in providing effective pre- or post-operative pain relief. 
Conclusion:  
The dissolution of LOR, a potent but insoluble NSAID, was successfully enhanced by 
producing a solid dispersion system through co-evaporation with PLU or a co-adsorbtion 
onto the surface of NEU with polysorbate 80. The LOR co-evaporate system with PLU 
displayed superior flow properties and was successfully manufactured into mini-tablets with 
directly compressible excipients. Whilst the mini-tablets comprising CEL showed higher 
tensile strengths at low compression pressures, incomplete drug release was evident during 
dissolution testing. Although, mini-tablets with DCP released > 90% of LOR within 15 min, 
the formulation of the LOR/ PLU co-evaporate system with STA showed superior flow 
properties together with rapid and complete dissolution of LOR from mini-tablets. Stability 
studies revealed that although different storage conditions affected the LOR content, in 
vitro release and tensile strength, the optimal mini-tablet formulation with STA showed 
superior characteristics after 3 months. Overall the in vivo pharmacokinetic profile and high 
absolute bioavailability demonstrate the potential of the formulation and the mini-tablets 
developed in this study to provide a rapid release multiparticulate formulation of LOR for 
dose flexibility and improved delivery to patients with swallowing difficulties.  
30 
 
References 
1. Homdrum, E. M., Likar, R., Nell, G. (2006). "Xefo® Rapid: A novel effective tool for pain treatment." 
European Surgery 38(5): 342-352. 
 
2. Schroeder, S., Heuser, A., Tellmann, A., Goebel, K.J., Woehrmann, T. (2012) Local tolerance of 
intraarticular administration of lornoxicam into the rabbit knee joint. Rheumatology International 
32(9): 2661-2667. 
 
3. Kidd, B., Frenzel, W. (1996) A multicenter, randomized, double blind study comparing lornoxicam 
with diclofenac in osteoarthritis." Journal of Rheumatology 23(9): 1605-1611 
 
4. Staunstrup, H., Ovesen, J., Larsen, U. T., Elbæk K., Larsen, U., Krøner, K. (1999). Efficacy and 
Tolerability of Lornoxicam versus Tramadol in Postoperative Pain. The Journal of Clinical 
Pharmacology 39(8): 834-841. 
 
5. Skjodt, N. M., Davies, N. M. (1998) Clinical Pharmacokinetics of Lornoxicam. Clinical 
Pharmacokinetics 34 (6) 421-428 
 
6. Gupta, M. K., Vanwert, A., Bogner, R. H. (2003) Formation of physically stable amorphous drugs by 
milling with NEU. Journal of Pharmaceutical Sciences 92(3): 536-551. 
 
7. Loftsson, T., Hreinsdóttir, D., Másson, M. (2005) Evaluation of cyclodextrin solubilization of drugs. 
International Journal of Pharmaceutics 302(1–2): 18-28 
 
31 
 
8. Abou-Taleb, A. E., Abdel-Rhman. A. A., Samy, E. M.,Tawfeek, H. M. (2006). "Interaction of 
Rofecoxib with ß-cyclodextrin and Hydroxypropyl ß-cyclodextrin in solution and in solid state " 
Bulletin of Pharmaceutical Scienece of Assiut University 29(2): 236-252 
 
9. Badr-Eldin, S. M., Elkheshen, S. A., Ghorab, M. M. (2008). "Inclusion complexes of tadalafil with 
natural and chemically modified β-cyclodextrins. I: Preparation and in-vitro evaluation." European 
Journal of Pharmaceutics and Biopharmaceutics 70(3): 819-827 
 
10. Cheng, Y.Y., Yang, J.P. (2006) Solubilization of non-steroidal anti-inflammatory drugs in the 
presence of tween series surfactants. Physics and Chemistry of Liquids 44(3): 249-256 
 
11. Seedher, N., Kanojia, M. (2008). Micellar Solubilization of Some Poorly Soluble Antidiabetic 
Drugs: A Technical Note." AAPS PharmSciTech 9(2): 431-436. 
 
12. Chauhan, B., Shimpi, S., Paradkar, A. (2005) Preparation and characterization of etoricoxib solid 
dispersions using lipid carriers by spray drying technique. AAPS PharmSciTech 6(3): E405-E409. 
 
13. El-Badry, M., Fetih, G., Fathy, M. (2009) Improvement of solubility and dissolution rate of 
indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi Pharmaceutical Journal 
17(3): 217-225 
 
14. Wu, K., Li, J., Wang, W.N., Winstead, D. A. (2009) Formation and characterization of solid 
dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with 
compressed antisolvent. Journal of Pharmaceutical Sciences 98(7): 2422-2431. 
 
32 
 
15. Gupta, M. K., Goldman, D., Bogner, R. H., Tseng, Y.C. (2001) Enhanced Drug Dissolution and Bulk 
Properties of Solid Dispersions Granulated with a Surface Adsorbent. Pharmaceutical Development 
and Technology 6(4): 563-572. 
 
16. Takeuchi, H., Nagira, S., Tanimura, S., Yamamoto, H., Kawashima, Y. (2005) Tabletting of Solid 
Dispersion Particles Consisting of Indomethacin and Porous Silica Particles. Chemical and 
Pharmaceutical Bulletin 53(5): 487-491. 
 
17. Wang, L., De Cui, F., Sunada, H. (2006). Preparation and Evaluation of Solid Dispersions of 
Nitrendipine Prepared with Fine Silica Particles Using the Melt-Mixing Method. Chemical and 
Pharmaceutical Bulletin 54(1): 37-43. 
 
18. Vadher, A. H., Parikh, J.R., Parikh, R. H., Solanki, A. B. (2009) Preparation and Characterization of 
Co-Grinded Mixtures of Aceclofenac and NEU US2 for Dissolution Enhancement of Aceclofenac. 
AAPS PharmSciTech 10(2): 606-614. 
 
19. World Health Organization (2012) Development of paediatric medicines – Points to consider in 
pharmaceutical development. 
 
20. Lennartz P., Mielck. J.B. (1998). "Minitabletting: improving the compactability of paracetamol 
powder mixtures." International Journal of Pharmaceutics 173: 75-85 
 
21. Mohamed, F. A. A., Roberts, M., Seton, L., Ford, J. L., Levina, M., Rajabi-Siahboomi, A. R. (2013) 
The influence of HPMC concentration on release of theophylline or hydrocortisone from extended 
release mini-tablets. Drug Development and Industrial Pharmacy 39(8): 1167-1174. 
 
33 
 
22. Dierickx, L., Saerens, L., Almeida A., De Beer, T., Remon, J.P., Vervaet, C. (2012). Co-extrusion as 
manufacturing technique for fixed-dose combination mini-matrices. European Journal of 
Pharmaceutics and Biopharmaceutics 81  683–689 
 
23. Lingam, M., Ashok, T., Venkateswarlu, V., Rao, Y.M. (2008) Design and evaluation of a novel 
matrix type multiple units as biphasic gastroretentive drug delivery systems. AAPS PharmSciTech 9 
1253-1261. 
 
24. Fell, J., Newton, JM. (1968). "The tensile strength of lactose tablets." Journal of Pharmacy and 
Pharmacology 20(8): 657-659 
 
25. Greenspan, L. (1977). "Humidity fixed points of binary staurated aqueous solutions." Journal of 
Research of the National Bureau of Standards - A, Physics and Chemistry 81A(1): 89-96. 
 
26. Apelblat, A. (1992). "The vapour pressures of water over saturated aqueous solutions of barium 
chloride, magnesium nitrate, calcium nitrate, potassium carbonate, and zinc sulfate, at temperatures 
from 283 K to 313 K." The Journal of Chemical Thermodynamics 24(6): 619-626 
 
27. International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use.  ICH Harmonised Triplicate Guideline on Validation of Analytical 
Procedures: Text and Methodology Q2 (R1). Available at: 
http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html 
28. Tan, A., Simovic, S., Davey, A.K., Rades, T., Prestidge, C.A. (2009) Silica lipid hybrid (SLH) 
microcapsules: A novel oral delivery system for poorly soluble drugs. Journal of Controlled Release 
134 62-70. 
 
34 
 
29. Rowland, M., Tozer, T. N. (2011) Absorption kinetics. Appendix F in: Clinical Pharmacokinetics 
and Pharmacodynamics: Concepts and Applications, 4thed. Lipincott, Williams and Wilkins, USA. 709-
712 
 
 30. Ghorab, D. M., Amin, M. M., Khowessah, O. M., Tadros, M. I. (2011) Colon-targeted celecoxib-
loaded Eudragit® S100-coated poly- ε-caprolactone microparticles: Preparation, characterization and 
in vivo evaluation in rats. Drug Delivery 18 (7) 523–535. 
 
31. Leonardi, D., Barrera, M. G., Lamas, M. C., Salomón, C. J. (2007) Development of prednisone: 
Polyethylene glycol 6000 fast-release tablets from solid dispersions: Solid-state characterization, 
dissolution behavior, and formulation parameters. AAPS PharmSciTech 8(4): 221-228 
 
32. Pathak, D., Dahiya, S., Pathak, K. (2008) Solid dispersion of meloxicam: Factorially designed 
dosage form for geriatric population. Acta Pharmaceutica 58(1): 99-110 
 
33. Ghareeb, M. M., Abdulrasool, A. A., Hussein, A. A., Noordin, M. I. (2009) Kneading Technique for 
Preparation of Binary Solid Dispersion of Meloxicam with Poloxamer 188. AAPS PharmSciTech 10(4): 
1206-1215 
 
34. O’Neill, M., Smith, A., Heckelman, P.E., Budavari, S., eds. (2001). The Merck Index, Whitehouse 
Station, NK, Merk & Co.Inc. 
 
35. Van den Mooter, G., Augustijns, P., Blaton, N., Kinget, R. (1998) Physico-chemical 
characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. 
International Journal of Pharmaceutics 164(1–2): 67-80. 
 
35 
 
36. Damian, F., Blaton, N., Naesens, L., Balzarini, J., Kinget, R., Augustijns, P., Van den Mooter, G. 
(2000) Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with 
polyethylene glycol 6000 and Gelucire 44/14. European Journal of Pharmaceutical Sciences 10(4): 
311-322 
 
37. Nair, R., Gonen, S., Hoag, S. W. (2002) Influence of polyethylene glycol and povidone on the 
polymorphic transformation and solubility of carbamazepine.  International Journal of 
Pharmaceutics 240(1–2): 11-22 
 
38. Kalaiselvan, R., Mohanta, G.P., Manna, P.K., Manavalan, R. (2006) Studies on mechanism of 
enhanced dissolution of albendazole solid dispersions with crystalline carriers. Indian Journal of 
Pharmaceutical Sciences 68(5): 599-607. 
 
39. Hamza, Y.E.S., Aburahma, M. H. (2010) Innovation of novel sustained release compression-
coated tablets for lornoxicam: formulation and in vitro investigations. Drug Development and 
Industrial Pharmacy 36(3): 337-349. 
 
40. Guyot, M., Fawaz, F., Bildet, J., Bonini, F., Lagueny, A. M. (1995). "Physicochemical 
characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid 
dispersions." International Journal of Pharmaceutics 123(1): 53-63. 
 
41. He, X.Q., Pei, L.X., Tong, H.H.Y., Zheng, Y. (2011) Comparison of Spray Freeze Drying and the 
Solvent Evaporation Method for Preparing Solid Dispersions of Baicalein with Pluronic F68 to 
Improve Dissolution and Oral Bioavailability." AAPS PharmSciTech 12(1): 104-113. 
 
36 
 
42. Ambike, A. A., Mahadik, K. R., Paradkar, A. (2004). "Stability study of amorphous valdecoxib." 
International Journal of Pharmaceutics 282(1–2): 151-162 
 
43. Shah, J., Vasanti, S., Anroop, B., Vyas, H. (2009) Enhancement of dissolution rate of valdecoxib by 
solid dispersions technique with PVP K 30 & PEG 4000: preparation and in vitro evaluation. Journal 
of Inclusion Phenomena and Macrocyclic Chemistry 63(1-2): 69-75. 
 
44. Qian, F., Tao, J., Desikan, S., Hussain, M., Smith, R. L. (2007) Mechanistic Investigation of 
Pluronic® Based Nano-crystalline Drug-polymer Solid Dispersions. Pharmaceutical Research 24(8): 
1551-1560 
 
45. Barzegar-Jalali, M., Maleki, N., Garjani, A., Khandar, A. A., Haji-Hosseinloo, M., Jabbari, R., 
Dastmalchi, S. (2002). "Enhancement of Dissolution Rate and Anti-inflammatory Effects of Piroxicam 
Using Solvent Deposition Technique." Drug Development and Industrial Pharmacy 28(6): 681-686 
 
46. Sharma, S., Sher, P., Badve, S., Pawar, A. P. (2005) Adsorption of meloxicam on porous calcium 
silicate: Characterization and tablet formulation. AAPS PharmSciTech 6(4): E618-E625. 
 
47. Ito, Y., Arai, H., Uchino, K., Iwasaki, K., Shibata, N., Takada, K. (2005a) Effect of adsorbents on the 
absorption of lansoprazole with surfactant." International Journal of Pharmaceutics 289(1–2): 69-77. 
 
48. Ito, Y., Kusawake, T., Ishida, M., Tawa, R., Shibata, N., Takada, K. (2005b) Oral solid gentamicin 
preparation using emulsifier and adsorbent. Journal of Controlled Release 105(1–2): 23-31. 
 
37 
 
49. Hassan Y.A., Shrif K., Samy E. M., Samy A. M., Kassem A. (2012) Improving the Availability and 
Bioavailability of Drug from Certain Pharmaceutical Dosage Forms. Ph.D. Thesis., Department of 
Pharmaceutics and Pharmaceutical Technology, Cairo University, Al-Azher Branch. 
 
50. Arida, A. I., Al-Tabakha, M. M. (2008). "CEL a Co-processed Excipient: A Comparison Study." 
Pharmaceutical Development and Technology 13(2): 165-175 
 
51. Saha, S., Shahiwala, A.F. (2009) Multifunctional coprocessed excipients for improved tabletting 
performance. Expert Opinion on Drug Delivery 6 197-208 
 
52. Hauschild, K., Picker, K.M. (2004) Evaluation of a new coprocessed compound based on lactose 
and maize starch for tablet formulation. AAPS PharmSci 6 27-38 
 
53. Jivraj, M., Martini, L.G., Thomson, C.M. (2000) An overview of the different excipients useful for 
the direct compression of tablets. Pharmaceutical  Science and Technology Today 3 58 -63 
 
54. Gohel, M.C., Jogani, P.D. (2005) A review of co-processed directly compressible excipients. 
Journal of Pharmacy and Pharmaceutical Sciences 8 76-93 
 
55. Casalderrey, M., Souto, C., Conchiero, A., Gomez-Mmoza, J.L., Martinez-Pacheco, R. (2004) A 
comparison of drug lodaing capacity of Cellactose® with two ad hoc processed lactose-cellulose 
direct compresion excipients. Chemical and Pharmaceutical Bulletin 52 (4) 398-401 
 
56. Mihranyan, A., Llagostera, A.P., Karmhag, R., Strømme, M., Ek, R. (2004) Moisture sorption by 
cellulose powders of varying crystallinity. International Journal of Pharmaceutics 269 433-442 
 
38 
 
57. Nilsson, M., Alderborn, G., Strømme, M. (2003) Water-induced charge transport in tablets of 
microcrystalline cellulose of varying density: dielectric spectroscopy and transient current 
measurements. Chemical Physics 295 159-165 
 
58. Khan, F., Pilpel, N., Ingram, S. (1988) The effect of moisture on the density, compaction and 
tensile strength of microcrystalline cellulose. Powder Technology 54 161-164 
 
59. Malamataris, S., Goidas, P., Dimitriou, A. (1991) Moisture sorption and tensile strength of some 
tableted direct compression excipients. International Journal of Pharmaceutics 68 51-60 
 
60. Amidon, G. E., Houghton, M. E. (1995) The effect of moisture on the mechanical and powder 
flow properties of microcrystalline cellulose. Pharmaceutical Research 12  923-929 
 
61. Sun, C.C. (2008) Mechanism of moisture induced variations in true density and compaction 
properties of microcrystalline cellulose. International Journal of Pharmaceutics 346  93-101 
 
62. Tawfeek, H.M. (2013) Lornoxicam suppositories; In-vitro formulation and in-vivo 
characterization. International Journal of Pharmaceutical Science and Research 4 4228-4235 
63. Balfour, J.A., Fitton, A., Barradell, L.B. (1996) Lornoxicam: A review of its pharmacology and 
therapeutic potential in the management of painful and inflammatory conditions. Drugs  51 639–657 
64. Hillstrom, C., Jakobsson, J.G. (2013) Lornoxicam: pharmacology and usefulness to treat acute 
postoperative and musculoskeletal pain a narrative review. Expert Opinion on Pharmacotherapy 14 
1679-1694 
39 
 
65. Yakhno, N., Guekht, A., Skoromets, A., Spirin, N., Strachunskaya, E., Ternavsky, A., Olsen, K.J., 
Moller, P.L. (2006) Analgesic Efficacy and Safety of Lornoxicam Quick-Release Formulation Compared 
With Diclofenac Potassium. Clinical Drug Investigation 26 267-277 
66. Mowafi, H.A., Telmessani, L., Ismail, S.A., Naguib, M.B. (2011) Preoperative lornoxicam for pain 
prevention after tonsillectomy in adults. Journal of Clinical Anesthesia. 23 97-101 
 
67. Ahmed, M.O., Al-Badr, A.A. (2011) Lornoxicam. Chapter 6 In: Brittain, H.G. (Ed) Profiles of Drug 
Substances, Excipients, and Related Methodology, Volume 36, Elsevier, USA, 205-239 
  
40 
 
FIGURES 
 
Fig. 1: FT-IR spectra of pure LOR, PEG, PLU, NEU and their physical mixtures, co-evaporate, 
adsorbate and co-adsorbate systems. 
(A) pure LOR (B) PEG (C) PLU (D) NEU (E) Physical mixture with PEG (1:5 wt. ratio); (F) Physical 
mixture with PLU (1:5 wt. ratio); (G) Physical mixture with NEU (1:5 wt. ratio); (H) co-evaporate with 
PEG (1:5 wt. ratio); (I) co-evaporate with PLU (1:5 wt. ratio); (J) adsorbate with NEU (1:5 wt. ratio); 
(K) co-adsorbate with NEU/polysorbate 80 (1:5:1 wt. ratios); (L) co-adsorbate with NEU/polysorbate 
80 (1:5:3 wt. ratios).   
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Fig. 2: DSC thermograms of pure LOR, PEG, PLU, NEU and their physical mixtures, co-evaporate, 
adsorbate and co-adsorbate systems. 
(A) pure LOR (B) PEG (C) PLU (D) NEU (E) Physical mixture with PEG (1:5 wt. ratio); (F) Physical 
mixture with PLU (1:5 wt. ratio); (G) Physical mixture with NEU (1:5 wt. ratio); (H) co-evaporate with 
PEG (1:5 wt. ratio); (I) co-evaporate with PLU (1:5 wt. ratio); (J) adsorbate with NEU (1:5 wt. ratio); 
(K) co-adsorbate with NEU/polysorbate 80 (1:5:1 wt. ratio); (L) co-adsorbate with NEU/polysorbate 
80 (1:5:3 wt. ratio).   
  
42 
 
 
Fig. 3: X-ray powder diffraction patterns of pure LOR, PEG, PLU, NEU and their physical mixtures, co-
evaporate, adsorbate and co-adsorbate systems. 
(A) pure LOR; (B) PEG; (C) PLU; (D) NEU; (E) Physical mixture with PEG (1:5 wt. ratio); (F) Physical 
mixture with PLU (1:5 wt. ratio); (G) Physical mixture with NEU US2 (1:5 wt. ratio); (H) co-evaporate 
with PEG (1:5 wt. ratio); (I) co-evaporate with PLU (1:5 wt. ratio); (J) adsorbate with NEU  (1:5 wt. 
ratio); (K) co-adsorbate with NEU/polysorbate 80 (1:5:1 wt. ratios); (L) co-adsorbate with 
NEU/polysorbate 80 (1:5:3 wt. ratios).   
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Fig. 4: In vitro dissolution profiles of LOR alone, physical mixtures, co-evaporate, adsorbate (1:5 
weight ratio) and co-adsorbate (1:5:1 and 1:5:3 weight ratio) systems (mean ± SD, n = 3). 
 
 
Fig. 5: The effect of compression pressure on the tensile strength of LOR mini-tablets formulated 
with different directly compressible excipients. 
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Fig. 6: In vitro dissolution profiles of LOR mini-tablets formulated with different directly compressible 
excipients (mean ± SD, n = 3). 
 
Fig. 7: In vitro dissolution profiles of LOR mini-tablets formulated with CEL after 3 months storage at 
different temperature and relative humidity conditions (mean ± SD, n = 3). 
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Fig. 8: In vitro dissolution profiles of LOR mini-tablets formulated with STA after 3 months storage at 
different temperature and relative humidity conditions (mean ± SD, n = 3). 
 
Fig. 9: In vitro dissolution profiles of LOR mini-tablets formulated with DCP after 3 months storage at 
different temperature and relative humidity conditions (mean ± SD, n = 3). 
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Fig. 10: In vivo plasma concentration–time profile for LOR following intravenous and oral 
administration to rabbits (mean ± SD, n = 3). 
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TABLES 
Table 1. The % compressibility (Carr’s Index) and Hausner Ratio (H) for Lornoxicam 
formulations (n=3 ± S.D.) 
 
 
 
 
Table 2. Tensile strength (MPa) of LOR mini-tablets formulated with different directly compressible 
excipients after 3 months storage under different conditions (mean ± SD, n = 4). No data could be 
obtained after storage at 75% RH/ 40°C as mini-tablets were too weak to test.  
 
 CEL DCP STA 
Ambient 1.76 ±0.01 1.20 ±0.05 1.2 ±0.15 
RT/43% RH 1.82 ±0.11 1.17 ±0.10 1.02 ±0.05 
RT/75% RH 1.94 ±0.09 0.77 ±0.11 1.01 ±0.10 
40°C/75% RH - - - 
 
  
LOR Formulation Carr’s Index (%) Hausner Ratio 
Co-evaporate with PLU (1:5 weight ratio) 27.62 ±4.01 1.38 ±0.07 
Co-adsorbate with NEU and polysorbate 80  
(1:5:3 weight ratio) 
44.48 ±0.9 1.80 ±0.02 
PLU co-evaporate + CEL 22.38 ±0.21 1.28 ±0.005 
PLU co-evaporate + STA 16.71 ±0.07 1.20 ±0.00 
PLU co-evaporate + DCP 
 
20.92 ±1.2 1.26 ±0.02 
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Table 3. Pharmacokinetic parameters of LOR after oral administration of mini-tablet and aqueous IV injection to rabbits (mean ± S.D., n=3 per 
group) 
 
Cmax: Maximum LOR concentration in plasma (µgml
-1); Tmax: Time to reach the maximum concentration after LOR administration (h); MRT: 
Mean residence time (h); Ka: absorption rate constant (h
-1); t1/2a: absorption half-life (h); Ke: Elimination rate constant (h
-1); t1/2e: Elimination 
half-life (h); AUC(0-24): The area under LOR plasma concentration time curve from (0-24, µg.hrml-
1); AUC(0-∞): The area under LOR plasma 
concentration time curve from zero to infinity (µg.hrml-1). * = significantly different compared to IV (p<0.05, ANOVA/Tukey’s). 
Treatment Cmax Tmax Ka t1/2a Ke t1/2e MRT AUC(0-24) AUC (0-∞) 
Mini-tablet (A) 3.33±0.19 2.0±0.0 1.1079±0.96 0.962±0.57 0.0863±0.01 *8.115±0.99 7.414±0.48 19.525±0.88 21.660±0.88 
IV injection (B) 3.72±0.18 -  -  -  0.1278±0.04 5.420±1.01 7.50±1.11 21.799±2.13 23.06±1.24 
